Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 7/20 | 0.38 |
| ▸ | NPC1 | O15118 | 5/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401847 | 0.83 | ALDH1A1 (0.49) | ALDH1A1KMT2AGAARAB9ANPC1 | |
| SCHEMBL20583542 | 0.81 | ALDH1A1 (0.57) | ALDH1A1KMT2AGAARAB9ANPC1 | |
| SCHEMBL28647743 | 0.77 | ALDH1A1 (0.47) | ALDH1A1KMT2AGAARAB9ANPC1 | |
| SCHEMBL25979693 | 0.77 | ALDH1A1 (0.50) | ALDH1A1KMT2AGAARAB9ANPC1 | |
| SCHEMBL20533552 | 0.76 | ALDH1A1 (0.56) | ALDH1A1KMT2AGAARAB9ANPC1 | |
| SCHEMBL272269 | 0.76 | ALDH1A1 (0.63) | ALDH1A1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL573354 | 0.76 | ALDH1A1 (0.63) | ALDH1A1KMT2ARAB9AMIFRECQL | |
| SCHEMBL182243 | 0.75 | ALDH1A1 (0.61) | ALDH1A1KMT2AGAARAB9ARECQL | |
| SCHEMBL20583517 | 0.75 | KMT2A (0.54) | ALDH1A1KMT2AGAARAB9ANPC1 | |
| SCHEMBL12779155 | 0.75 | ALDH1A1 (0.61) | ALDH1A1KMT2AGAARAB9ARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670216-B2 | Cannabinoid-2 agonists | ALLERGAN, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| EP-2957560-A1 | PYRIDAZINE DERIVATIVES USEFUL AS CANNABINOID-2 AGONISTS | ALLERGAN, INC. (US) | 2015-12-23 | — | — | EP | disclosed |
| US-20150284400-A1 | CANNABINOID-2 AGONISTS | ALLERGAN, INC. | 2015-10-08 | — | — | US | disclosed |
| EP-2534137-B1 | PYRIDAZINE DERIVATIVES USEFUL AS CANNABINOID-2 AGONISTS | ALLERGAN INC (US) | 2015-09-16 | — | — | EP | disclosed |
| US-9062004-B2 | Cannabinoid-2 agonists | ALLERGAN, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20130059848-A1 | CANNABINOID-2 AGONISTS | ALLERGAN, INC (US) | 2013-03-07 | — | — | US | disclosed |
| EP-2534137-A1 | PYRIDAZINE DERIVATIVES USEFUL AS CANNABINOID - 2 AGONISTS | Allergan, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011097553-A1 | PYRIDAZINE DERIVATIVES USEFUL AS CANNABINOID - 2 AGONISTS | ALLERGAN, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284400-A1 | CANNABINOID-2 AGONISTS | CNR2, CNR1, GPR18 | ALDH1A1 3394/4885KMT2A 1443/4885GAA 3045/4885 |
| US-20130059848-A1 | CANNABINOID-2 AGONISTS | CNR2, CNR1, GPR18 | ALDH1A1 2618/4885KMT2A 1864/4885GAA 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.